Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.

Stock Quote Today & Recent News NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Our first product ExoPTEN for acute spinal cord injury has been granted Orphan Drug Designation by the FDA.

Dr. Lior Shaltiel

Current News (TSXV:NRX)

NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets

GlobeNewswire 12 days ago

NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update

GlobeNewswire November 1, 2024

NurExone's Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

GlobeNewswire October 23, 2024

NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M

GlobeNewswire September 26, 2024

NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences

GlobeNewswire September 12, 2024

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

GlobeNewswire September 6, 2024
View More News ››

We are developing a unique and futuristic drug delivery system—exosomes deliver therapeutic cargo to tissues and organs, promoting a healing environment for neuroregeneration.

Dr. Lior Shaltiel

Opinion & Analysis (TSXV:NRX)

Revolutionary biopharma company makes waves across the globe

Lyndsay Malchuk July 10, 2024

ExoTherapy offers hope for treating acute spinal cord injuries

Brieanna McCutcheon  September 19, 2023
View More Opinion ››

Bullboard Posts (TSXV:NRX)

More exciting news!

https://stockhouse.com/news/press-releases/2024/11/13/nurexone-biologic-secures-ema-orphan-status-for-exopten-in-spinal-cord-injury
GoldCanuck28 - 12 days ago

What a great company!

Watching this company very closely I see great things on the Horizon
DPSMAN7 - 12 days ago

Watching this closely… time to get involved?

Nurexone Biologic just closed their final private placement round! Could this signal strong growth ahead?
GoldCanuck28 - 13 days ago

NurExone’s Regenerative Medicine Therapies To Be Recognized

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA (TSXV: NRX, OTCQB: NRXBF) https://www...
Mathew177 - October 23, 2024

Why NRX Could Be the Next DRUG Success Story

Why NRX Could Be the Next DRUG Success Story (TSXV: NRX, OTCQB: NRXBF) https://10xalerts.com/why-nrx-could-be-the-next-drug-success...
Mathew177 - October 16, 2024

Initiating Coverage of Nurexone: Potential Breakthrough

Initiating Coverage of Nurexone: Potential Breakthrough Treatment for Spinal Injuries (TSXV: NRX, OTCQB: NRXBF) https://pdfhost.io/v...
ElliotGH - October 3, 2024
View more Bullboard ››

Connect with V.NRX

Visit Facebook Visit X Visit Linked In Visit Youtube

PRESENTATION TECHNOLOGY - EXOSOMES TECHNOLOGY - EXOTHERAPY MANAGEMENT ANALYST REPORT LEARN ABOUT ODD

Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.

Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu